Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DYN Dyne Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: DYN
Price (delayed)
$11.295
Market cap
$1.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.59
Enterprise value
$833M
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in
Highlights
The equity has grown by 40% YoY and by 6% from the previous quarter
Dyne Therapeutics's quick ratio has increased by 32% from the previous quarter
DYN's EPS is up by 10% year-on-year but it is down by 7% since the previous quarter
DYN's net income is down by 43% YoY and by 16% QoQ
Key stats
What are the main financial stats of DYN
Market
Valuations
Earnings
Shares outstanding
113.67M
Market cap
$1.28B
Enterprise value
$833M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$397.1M
Net income
-$367.13M
EBIT
-$367.13M
EBITDA
-$364.87M
Free cash flow
-$322.89M
Per share
Balance sheet
Liquidity
EPS
-$3.59
EPS diluted
-$3.59
Free cash flow per share
-$2.94
Book value per share
$5.91
Revenue per share
$0
TBVPS
$6.56
Total assets
$721.07M
Total liabilities
$52.1M
Debt
$23.33M
Equity
$668.97M
Working capital
$655.62M
Debt to equity
0.03
Current ratio
20.35
Quick ratio
20.05
Net debt/EBITDA
1.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.8%
Return on equity
-52.8%
Return on invested capital
-163.2%
Return on capital employed
-53.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DYN stock price
How has the Dyne Therapeutics stock price performed over time
Intraday
20.16%
1 week
-5.8%
1 month
65.86%
1 year
-56.03%
YTD
-52.06%
QTD
7.98%
Financial performance
How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$397.1M
Net income
-$367.13M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 49% YoY and by 15% QoQ
DYN's net income is down by 43% YoY and by 16% QoQ
Price vs fundamentals
How does DYN's price correlate with its fundamentals
Growth
What is Dyne Therapeutics's growth rate over time
Valuation
What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is up by 10% year-on-year but it is down by 7% since the previous quarter
The price to book (P/B) is 48% lower than the last 4 quarters average of 3.7 and 38% lower than the 5-year quarterly average of 3.1
The equity has grown by 40% YoY and by 6% from the previous quarter
Efficiency
How efficient is Dyne Therapeutics business performance
The return on equity has surged by 52% year-on-year but it has declined by 8% since the previous quarter
The company's return on assets rose by 46% YoY but it fell by 8% QoQ
DYN's return on invested capital is up by 32% year-on-year but it is down by 18% since the previous quarter
Dividends
What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DYN.
Financial health
How did Dyne Therapeutics financials performed over time
The company's total assets rose by 38% YoY and by 4.3% QoQ
Dyne Therapeutics's quick ratio has increased by 32% from the previous quarter
The debt is 97% smaller than the equity
Dyne Therapeutics's debt to equity has shrunk by 50% YoY and by 25% QoQ
The equity has grown by 40% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.